SG10201705518SA - Age-Related Macular Degeneration Treatment - Google Patents
Age-Related Macular Degeneration TreatmentInfo
- Publication number
- SG10201705518SA SG10201705518SA SG10201705518SA SG10201705518SA SG10201705518SA SG 10201705518S A SG10201705518S A SG 10201705518SA SG 10201705518S A SG10201705518S A SG 10201705518SA SG 10201705518S A SG10201705518S A SG 10201705518SA SG 10201705518S A SG10201705518S A SG 10201705518SA
- Authority
- SG
- Singapore
- Prior art keywords
- age
- macular degeneration
- related macular
- degeneration treatment
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21047—Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361750086P | 2013-01-08 | 2013-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201705518SA true SG10201705518SA (en) | 2017-08-30 |
Family
ID=51166430
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201705518SA SG10201705518SA (en) | 2013-01-08 | 2014-01-08 | Age-Related Macular Degeneration Treatment |
SG11201505272QA SG11201505272QA (en) | 2013-01-08 | 2014-01-08 | Age-related macular degeneration treatment |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201505272QA SG11201505272QA (en) | 2013-01-08 | 2014-01-08 | Age-related macular degeneration treatment |
Country Status (13)
Country | Link |
---|---|
US (2) | US10000753B2 (ko) |
EP (1) | EP2943571A4 (ko) |
JP (1) | JP2016507514A (ko) |
KR (1) | KR20150103280A (ko) |
CN (1) | CN105143450A (ko) |
AU (1) | AU2014205036A1 (ko) |
CA (1) | CA2897342A1 (ko) |
HK (1) | HK1218656A1 (ko) |
IL (1) | IL239836A0 (ko) |
MX (1) | MX2015008697A (ko) |
RU (1) | RU2015133252A (ko) |
SG (2) | SG10201705518SA (ko) |
WO (1) | WO2014107763A1 (ko) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160251410A1 (en) | 2013-09-03 | 2016-09-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
BR112016013148B1 (pt) * | 2013-12-12 | 2024-02-27 | Alnylam Pharmaceuticals, Inc | ÁCIDO RIBONUCLEICO DE FITA DUPLA (dsRNA) PARA INIBIÇÃO DA EXPRESSÃO DO FATOR B DO COMPLEMENTO (CFB) EM UMA CÉLULA, COMPOSIÇÃO FARMACÊUTICA PARA INIBIÇÃO DA EXPRESSÃO DE UM GENE DO FATOR B DO COMPLEMENTO, SEU USO, E MÉTODO IN VITRO DE INIBIÇÃO DA EXPRESSÃO DO FATOR B DO COMPLEMENTO (CFB) EM UMA CÉLULA |
IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | NMDA receptor antagonists for the treatment of Gaucher disease |
KR20230145206A (ko) * | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
CN107109407A (zh) | 2014-11-14 | 2017-08-29 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
EP4218771A1 (en) | 2015-03-27 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods of treating motor neuron diseases |
US20180161300A1 (en) | 2015-05-11 | 2018-06-14 | Yeda Research And Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
EP3744340A3 (en) | 2015-07-16 | 2021-03-03 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
EP3405024B1 (en) | 2016-01-21 | 2022-12-28 | The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Parthenocarpic plants and methods of producing same |
US20190046497A1 (en) | 2016-02-14 | 2019-02-14 | Yeda Research And Development Co., Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
WO2017148904A1 (en) * | 2016-02-29 | 2017-09-08 | Franz Grus | Predictive markers useful in the treatment of wet age-related macular degeneration |
US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
CA3024449A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
WO2018117253A1 (ja) * | 2016-12-23 | 2018-06-28 | 協和発酵キリン株式会社 | 補体b因子の発現を抑制する核酸 |
WO2018141025A1 (en) * | 2017-02-03 | 2018-08-09 | Benitec Biopharma Limited | Reagents for treatment of ocular diseases and conditions associated with neovascularisation and use thereof |
MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)治療組成物および方法 |
IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Treatment of stress disorders |
WO2019005926A1 (en) * | 2017-06-27 | 2019-01-03 | Massachusetts Eye And Ear Infirmary | VEGFR2 AAV-CRISPR / CAS9 GENOME EDITION FOR THE TREATMENT OF OCULAR DISEASES |
IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combined treatment for cancer |
BR112020005103A2 (pt) * | 2017-09-15 | 2020-09-24 | Commonwealth Scientific And Industrial Research Organisation | molécula de rna, molécula de ácido ribonucleico (rna) quimérica, polinucleotídeo isolado e/ou exógeno, vetor, célula hospedeira, polinucleotídeo, organismo não humano, método, método para produzir um organismo não humano, extrato de uma célula hospedeira, composição, método para regular de modo decrescente o nível e/ou a atividade de uma molécula de rna-alvo em um organismo, método para controlar um organismo não humano, método para tratar uma doença em um indivíduo, molécula de rna, uso de uma molécula de rna e kit |
KR20230050424A (ko) | 2017-09-19 | 2023-04-14 | 트로픽 바이오사이언시즈 유케이 리미티드 | 유전자 발현을 침묵시키기 위한 식물의 비-암호화 rna 분자의 특이성 변형 |
CA3078971A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with enhanced properties |
IL262658A (en) | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
GB201903519D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest |
GB201903520D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells |
GB201903521D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | No title |
IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
EP4299588A3 (en) * | 2019-09-10 | 2024-03-20 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Treatment methods for eye disorders |
IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
EP4096647A1 (en) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Treating acute liver disease with tlr-mik inhibitors |
WO2022079719A1 (en) | 2020-10-15 | 2022-04-21 | Yeda Research And Development Co. Ltd. | Method of treating myeloid malignancies |
EP4263832A2 (en) | 2020-12-18 | 2023-10-25 | Yeda Research and Development Co. Ltd | Compositions for use in the treatment of chd2 haploinsufficiency and methods of identifying same |
EP4267741A2 (en) | 2020-12-28 | 2023-11-01 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
AU2021416356A1 (en) | 2020-12-28 | 2023-08-10 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
GB202103256D0 (en) | 2021-03-09 | 2021-04-21 | Tropic Biosciences Uk Ltd | Method for silencing genes |
BR112023023486A2 (pt) | 2021-05-10 | 2024-01-30 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Composição farmacêutica, e, método de tratamento de uma doença ou condição na qual um efeito clínico benéfico é obtido pela redução na atividade de sintase de óxido nítrico neuronal |
AU2022336157A1 (en) * | 2021-09-02 | 2024-03-14 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell |
WO2023062636A1 (en) | 2021-10-14 | 2023-04-20 | Weedout Ltd. | Methods of weed control |
WO2023076451A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517864B2 (en) * | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
US7309487B2 (en) * | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
AU2005222084B2 (en) * | 2004-03-05 | 2010-04-22 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of RNAI agents |
ES2423060T3 (es) * | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
US8282921B2 (en) * | 2004-08-02 | 2012-10-09 | Paul Glidden | tRNA synthetase fragments |
AU2006210443B2 (en) * | 2005-02-03 | 2011-01-27 | Benitec, Inc. | RNAi expression constructs |
CN101228176A (zh) * | 2005-04-28 | 2008-07-23 | 贝尼泰克有限公司 | 用于同时递送与杂合表达模式相关的RNAi因子的多重RNAi表达盒 |
JP5078904B2 (ja) * | 2005-11-21 | 2012-11-21 | ジヨンソン・アンド・ジヨンソン・リサーチ・ピーテイワイ・リミテツド | 多標的干渉rnaならびにそれらの使用および設計方法 |
GB0608838D0 (en) * | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
EP2494993B1 (en) * | 2007-05-04 | 2018-08-01 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
WO2008154482A2 (en) * | 2007-06-08 | 2008-12-18 | Sirnaomics, Inc. | Sirna compositions and methods of use in treatment of ocular diseases |
WO2009048932A2 (en) * | 2007-10-09 | 2009-04-16 | Children's Medical Center Corporation | Methods to regulate mirna processing by targeting lin-28 |
EP2361306A1 (en) * | 2008-12-04 | 2011-08-31 | OPKO Ophthalmics, LLC | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
MX2013000986A (es) * | 2010-07-28 | 2013-07-03 | Alcon Res Ltd | Sirna dirigido al vegfa y metodos de tratamiento in vivo. |
US9220716B2 (en) * | 2011-07-26 | 2015-12-29 | Children's Medical Center Corporation | Methods and compositions for the treatment of proliferative vascular disorders |
AU2013225619A1 (en) | 2012-02-29 | 2014-10-16 | Benitec Biopharma Limited | Pain treatment |
-
2014
- 2014-01-08 SG SG10201705518SA patent/SG10201705518SA/en unknown
- 2014-01-08 US US14/759,401 patent/US10000753B2/en active Active
- 2014-01-08 SG SG11201505272QA patent/SG11201505272QA/en unknown
- 2014-01-08 MX MX2015008697A patent/MX2015008697A/es unknown
- 2014-01-08 JP JP2015551090A patent/JP2016507514A/ja not_active Ceased
- 2014-01-08 CA CA2897342A patent/CA2897342A1/en not_active Abandoned
- 2014-01-08 CN CN201480010251.6A patent/CN105143450A/zh active Pending
- 2014-01-08 EP EP14737958.0A patent/EP2943571A4/en not_active Withdrawn
- 2014-01-08 WO PCT/AU2014/000007 patent/WO2014107763A1/en active Application Filing
- 2014-01-08 RU RU2015133252A patent/RU2015133252A/ru not_active Application Discontinuation
- 2014-01-08 AU AU2014205036A patent/AU2014205036A1/en not_active Abandoned
- 2014-01-08 KR KR1020157021273A patent/KR20150103280A/ko not_active Application Discontinuation
-
2015
- 2015-07-08 IL IL239836A patent/IL239836A0/en unknown
-
2016
- 2016-06-08 HK HK16106608.3A patent/HK1218656A1/zh unknown
-
2018
- 2018-04-27 US US15/964,584 patent/US20180320180A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG11201505272QA (en) | 2015-08-28 |
RU2015133252A (ru) | 2017-02-10 |
AU2014205036A1 (en) | 2015-07-30 |
EP2943571A4 (en) | 2016-11-30 |
US10000753B2 (en) | 2018-06-19 |
IL239836A0 (en) | 2015-08-31 |
US20180320180A1 (en) | 2018-11-08 |
US20160145611A1 (en) | 2016-05-26 |
EP2943571A1 (en) | 2015-11-18 |
KR20150103280A (ko) | 2015-09-09 |
CA2897342A1 (en) | 2014-07-17 |
MX2015008697A (es) | 2016-08-04 |
JP2016507514A (ja) | 2016-03-10 |
HK1218656A1 (zh) | 2017-03-03 |
CN105143450A (zh) | 2015-12-09 |
WO2014107763A1 (en) | 2014-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1218656A1 (zh) | 年齡相關性黃斑變性治療 | |
HK1222994A1 (zh) | 烟草處理 | |
HK1217490A1 (zh) | 黃斑變性治療中的新穎捕獲劑 | |
IL266651B (en) | graft | |
HK1217452A1 (zh) | 含有前列腺胺的眼内植入物 | |
GB201308131D0 (en) | Ophthalmoscope | |
EP2945639A4 (en) | METHOD FOR THE TREATMENT OF HEART DISEASES | |
HK1215164A1 (zh) | 處理方法 | |
SG11201508297YA (en) | Compositions and methods for treating and preventing macular degeneration | |
GB201304872D0 (en) | Treatment | |
GB201308244D0 (en) | Soil treatment | |
HK1214093A1 (zh) | 烟草處理 | |
GB201616158D0 (en) | Age-related macular degeneration | |
HK1216391A1 (zh) | 組合治療 | |
PL2826522T3 (pl) | Rozrusznik serca | |
GB201307310D0 (en) | Treatment | |
PT2777699T (pt) | Dietilamina-2,5-di-hidroxibenzenossulfonato para o tratamento de degeneração macular relacionada com a idade | |
GB2514124B (en) | Turf Treatment | |
GB201321115D0 (en) | Treatment | |
GB201309238D0 (en) | Treatment | |
IL230230A0 (en) | graft | |
GB201322764D0 (en) | Treating places | |
GB201310756D0 (en) | Implant |